Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice.

Pathologica - 1 Apr 2023

Angerilli Valentina, Fornaro Lorenzo, Pepe Francesco, Rossi Silvia Maria, Perrone Giuseppe, Malapelle Umberto, Fassan Matteo

Abstract excerpt

Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms burdened by a dismal prognosis. Several studies have investigated the genomic profile of CCA and identified numerous druggable genetic alterations, including FGFR2 fusions/rearrangements. Approximately 5-7% of CCAs and 10-20% of intrahepatic iCCAs harbor FGFR2 fusions. With the recent advent of FGFR-targeting therapies into clinical practice, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Bile Ducts, Intrahepatic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Cholangiocarcinoma and Gallbladder Cancer Studies

Share to Fibroblast Growth Factor Research

Share to Mutation

Share to Prognosis

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Open in PubMed Open full text

Identifiers

PMID: 37017301
DOI: 10.32074/1591-951X-859
PMCID: PMC10462997

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice.PMID 37017301Read ↗

Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?Semantic proximity Read ↗

Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingSemantic proximity Read ↗

FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISHSemantic proximity Read ↗

Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing.Semantic proximity Read ↗

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read ↗

Comparative Analysis of Molecular Testing Methods for FGFR2 Fusion/Rearrangement in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paperSemantic proximity Read ↗

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.Semantic proximity Read ↗

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomasSemantic proximity Read ↗

Role of molecular genetics in the clinical management of cholangiocarcinomaSemantic proximity Read ↗

Practical considerations in screening for genetic alterations in cholangiocarcinoma.Semantic proximity Read ↗

FGFR2 Inhibition in Cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.